Navigation Links
Oridion Announces Major Medical Research and Congress Presentations
Date:6/16/2008

JERUSALEM and NEEDHAM, Massachusetts, June 17 /PRNewswire-FirstCall/ -- Oridion Systems Ltd. - (SWX: ORIDN) Significant findings from numerous medical research projects demonstrating the clinical benefit of end-tidal CO2 (EtCO2) monitoring using Microstream(R) capnography technology, were recently presented at medical congresses in the United States and Europe.

During Digestive Disease Week (DDW) in San Diego, California, Dr. Vargo, of the Cleveland Clinic, presented a blinded study that analyzed 122 randomized patients and showed that Microstream(R) capnography "significantly reduces the proportion of patients with hypoxemia, major hypoxemia, apnea and oxygen requirements during ERCP (Endoscopic Retrograde Cholangiopancreatography) and EUS (Endoscopic ultrasound).

Other studies describing the clinical value of Microstream(R) EtCO2 monitoring were presented during the European Resuscitation Council (ERC) in Ghent, Belgium and the European Society of Anesthesiology (ESA) in Copenhagen, Denmark. At ERC, two oral presentations were given and a Capnography Symposium took place with three distinguished clinicians and the clinical practice manager from London Ambulance Service. The four presentations showed the value of capnography in pre-hospital care (trauma, intubations, and ROSC). The Symposium was moderated by Prof. Pierre Carli, President Societe Francaise d'Anesthesie et de Reanimation (French Society of Anesthesia and Intensive Care).

Two medical presentations given at European Society of Anesthesia demonstrated the importance of capnography for non-intubated and intubated patients. In a study on the use of continuous non-invasive arterial CO2 estimation in spontaneously breathing patients after craniotomy, Dr. Wolter from France showed a good correlation between capnography and arterial blood gas analysis in sedated patients under regional anesthesia.

"These recent studies continue to confirm that patients are safer when their c
'/>"/>

SOURCE Oridion Systems Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)...TER, N.J., Dec. 1 Tibotec Therapeu...s, L.P., announced today that it is launching a ne...g women and people of color living with HIV/AIDS. ...ducational events, media outreach and a new Web si...g learnings from the GRACE study, the largest clin...
(Date:12/1/2009)...D CITY, Calif., Dec. 1 Codexis, In...p and the signing of its second agreement this yea...rld,s largest generic drug manufacturer. The new ...products. Codexis announced an earlier agreement ...ent, Teva will use Codexis biocatalysis technology...
(Date:12/1/2009)...STON, Dec. 1 An expert f...XL ), a leading global biopharmaceutical services ...ve approaches to drug development in Asia at the P...ence, being held December 1-3, 2009 at the Interco... of the conference, which is focused on maximizing...
Breaking Medicine Technology:Tibotec Therapeutics Launches GRACE Campaign for Women and People of Color Living With HIV/AIDS 2Tibotec Therapeutics Launches GRACE Campaign for Women and People of Color Living With HIV/AIDS 3Tibotec Therapeutics Launches GRACE Campaign for Women and People of Color Living With HIV/AIDS 4Tibotec Therapeutics Launches GRACE Campaign for Women and People of Color Living With HIV/AIDS 5Tibotec Therapeutics Launches GRACE Campaign for Women and People of Color Living With HIV/AIDS 6Tibotec Therapeutics Launches GRACE Campaign for Women and People of Color Living With HIV/AIDS 7Codexis Expands Collaboration with Teva 2PAREXEL Expert To Lead Panel on Innovative Drug Development in Asia at Partnerships in Clinical Trials Asia Pacific Conference 2PAREXEL Expert To Lead Panel on Innovative Drug Development in Asia at Partnerships in Clinical Trials Asia Pacific Conference 3PAREXEL Expert To Lead Panel on Innovative Drug Development in Asia at Partnerships in Clinical Trials Asia Pacific Conference 4What scientists know about jewel beetle shimmer 9338 1What scientists know about jewel beetle shimmer 9338 2R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies Results Incongruent 4774 1R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies Results Incongruent 4774 2R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies Results Incongruent 4774 3R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies Results Incongruent 4774 4R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies Results Incongruent 4774 5R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies Results Incongruent 4774 6R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies Results Incongruent 4774 7R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies Results Incongruent 4774 8Renaissance Grants 243 000 to the Florida Dental Association to Present Oral Health Workshops for the Vulnerable Elderly 52615 1Renaissance Grants 243 000 to the Florida Dental Association to Present Oral Health Workshops for the Vulnerable Elderly 52615 2Renaissance Grants 243 000 to the Florida Dental Association to Present Oral Health Workshops for the Vulnerable Elderly 52615 3
...ogentus Pharmaceuticals,Inc. today announced that ...e full antiplatelet activity of its novel combinat...psule that combines clopidogrel (currently,markete...s Plavix(R)) with,a gastroprotectant (omeprazole) ...elet therapy., (Logo: http://www.newscom.com/cgi...
...fety Profile and Favorable Pharmacokinetics ... TRIANGLE PARK, N.C., Jan. 16 CeNeRx BioPharma,In...cializing innovative,treatments for diseases of th...essful completion of the Phase l clinical program ...nt of depression and anxiety. Tyrima is a,selectiv...
Other Medicine Technology:Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168 2CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM) 2CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM) 3
(Date:12/1/2009)... 1 With employee benefit...f employers are providing self-service decision-ma...n, according to a new survey by Watson Wyatt, a le...ers who offer these tools believe they lead employ... According to the survey, 45 percent of companies ...
(Date:12/1/2009)...Dec. 1 On December 31, ...federal prisoners were HIV positive or had confirm... the Office of Justice Programs, U.S. Department o...timated 5,672 inmates in state and federal prisons...007, about 43 per 10,000 prison inmates were estim...
(Date:12/1/2009)... and South America, study finds , , TUES...f intensive care unit patients worldwide suffer in...e hospital, a new study finds. , Researchers an...) on 13,796 patients, aged 18 and older, in 1,265 ...f patients were classified as infected and 71 perc...
(Date:12/1/2009)...2009) Wistar Institute researchers and collaborat...rk University have identified immune system marker...ors in people at high risk for developing lung can... Cancer Research , a journal of the American Assoc... blood test to detect lung cancer in its earliest ...
(Date:12/1/2009)...GLE PARK, N.C., Dec. 1 Max Neeman ...expanded over the years serving the top most pharm...as originally set up in an area of 2000 sq. ft. ha...of the suite of services by Max Neeman, are recogn...ffering. ,, The pharmacy inventory management p...
Breaking Medicine News(10 mins):Health News:Employers Plan to Increase Use of Self-Service Decision-Making Technology For Open Enrollment, Watson Wyatt Survey Finds 2Health News:Employers Plan to Increase Use of Self-Service Decision-Making Technology For Open Enrollment, Watson Wyatt Survey Finds 3Health News:Rate of Confirmed AIDS in Prison 2.5 Times the Rate in the U.S. General Population 2Health News:Rate of Confirmed AIDS in Prison 2.5 Times the Rate in the U.S. General Population 3Health News:Half of ICU Patients Suffer From Infections 2Health News:Wistar-led research team discovers genetic pattern that indicates early-stage lung cancer 2Health News:Wistar-led research team discovers genetic pattern that indicates early-stage lung cancer 3
...elieve they eat a lot of meat because of the taste...the Journal of Consumer Research, the reason tha... to some people has more to do with values than ac...r Food Industries and Management, France) conducte...
...called a primary stumbling block , , THURS...care in the United States continues to elude more ...ore, since the first "scorecard" was done in 2006,...on. , These are some of the findings in the Common...
...vest Products,Inc. (OTC Bulletin Board: FRHV.OB) a...its long standing commitment to providing consumer...ings, through a new initiative to,build natural an...lieve that this new initiative is a natural and lo...
... Digital Documents, a,provider of turnkey, cost-ef...d HCAHPS Surveys, announced today the integration ... Health Systems, the largest,not-for-profit Protes...e expensive," commented Bruce,Genger, President of...
...January 2, 2009 -, LAVAL, QC, July 17 /PRNewswire...SS) today announced that the response that it subm...A) on July 2, 2008, including the,additional analy...cription Drug User Fee Act (PDUFA) is January 2, 2...
...IGNA, the health service company, launched its new...ents in the Wall Street Journal. Supported by Dore...gn will be the largest in CIGNA's history, an... Philadelphia, PA (PRWEB) July 1...
Other Medicine News:Health News:Good news for veggies 2Health News:U.S. Health Care Still Ill, Survey Finds 2Health News:U.S. Health Care Still Ill, Survey Finds 3Health News:Fresh Harvest Products, Inc. Announces New Brand Initiative 2Health News:Innovative HCAHPS Patient Satisfaction Survey Solution Generates Huge Cost-Savings Opportunity for Adventist Health Systems 2Health News:FDA accepts Labopharm's response for once-daily tramadol as complete Class 2 response 2Health News:CIGNA Launches National "It's Time to Feel Better" Advertising Campaign to Support Health Service Mission 2Health News:CIGNA Launches National "It's Time to Feel Better" Advertising Campaign to Support Health Service Mission 3
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
Medicine Products: